BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
Key Highlights
- ➤Q3 revenue $2.94 billion, up 10% reported and 8% organically
- ➤Adjusted EPS $1.77, up 53% from $1.16
- ➤Adjusted EBITDA $1.305 billion, up 32% year over year
- ➤2026 guidance raised for revenue, Adjusted EBITDA, and adjusted operating cash flow
- ➤Board authorized $50 million share repurchase program to offset 2027 equity-award dilution
Expert Statements
Thomas J. Appio, Chief Executive Officer of Bausch Health
“Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth. We also achieved an important milestone, with quarterly Adjusted EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time. Our performance reflects disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter. These results give us confidence to again raise our full year 2026 guidance. We remain focused on operational excellence, sustainable growth, and long-term value creation”
BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE PR Newswire
* Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic(1) basis over the prior year period * GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million * GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share(1) of $1.77 compared to $1.16 in the prior year period, an increase of 53% * Consolidated Adjusted EBITDA Attributable to Bausch Health(1) of $1,305 million, up 32% over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2026 RESULTS
Get started
Create a free account to read the full story.